

Inflammatory Pain - Pipeline Insight, 2021

https://marketpublishers.com/r/I50B740D2D2FEN.html

Date: February 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: I50B740D2D2FEN

Abstracts

This report can be delivered to the clients within 48-72 Hours

DelveInsight's, "Inflammatory Pain - Pipeline Insight, 2021," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in the Inflammatory Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Inflammatory Pain Understanding

Inflammatory Pain: Overview

Inflammatory pain is associated with inflammatory response due to harmful stimuli. The damaged tissue because of an external stimuli is responsible for the activation of inflammatory mediators which leads to potentiation of pain. The inflammatory process plays a protective role by activating the immune system but it can also exacerbate painful symptoms. Symptoms can include redness, joint pain, fever, swollen area that might be warm to touch.

"Inflammatory Pain - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Inflammatory Pain pipeline landscape is provided which



includes the disease overview and Inflammatory Pain treatment guidelines. The assessment part of the report embraces, in depth Inflammatory Pain commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Inflammatory Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Inflammatory Pain R&D. The therapies under development are focused on novel approaches to treat/improve Inflammatory Pain.

Inflammatory Pain Emerging Drugs Chapters

This segment of the Inflammatory Pain report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Inflammatory Pain Emerging Drugs

CNTX 6970: Centrexion Therapeutics

Centrexion's lead drug candidate, CNTX 6970 is an orally administered small molecule in development for the treatment of inflammatory pain. The drug is a CCR 2 receptor antagonist with dual effects. It inhibits the immune cells from releasing potent cytokine CCL2 and further stop it from stimulating pain fibers and from sending signals for pain.

Further product details are provided in the report......

Inflammatory Pain: Therapeutic Assessment

This segment of the report provides insights about the different Inflammatory Pain drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Inflammatory Pain



There are approx. 3+ key companies which are developing the therapies for Inflammatory Pain. The companies which have their Inflammatory Pain drug candidates in the most advanced stage, i.e. phase II include, Centrexion Therapeutics.

Phases

DelveInsight's report covers around 3+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Inflammatory Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Subcutaneous

Topical

Intravenous

Molecule Type

Products have been categorized under various Molecule types such as



Monoclonal Antibody

Peptides

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Inflammatory Pain: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Inflammatory Pain therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Inflammatory Pain drugs.

Inflammatory Pain Report Insights

Inflammatory Pain Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Inflammatory Pain Report Assessment

Pipeline Product Profiles



Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Inflammatory Pain drugs?

How many Inflammatory Pain drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Inflammatory Pain?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Inflammatory Pain therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Inflammatory Pain and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Centrexion Therapeutics

Key Products



CNTX 6970



Contents

Introduction

Executive Summary

Inflammatory Pain: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Inflammatory Pain - DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Inflammatory Pain companies' collaborations, Licensing, Acquisition -Deal Value

Trends

Inflammatory Pain Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Mid Stage Products (Phase II)

Comparative Analysis

CNTX 6970: Centrexion Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

AAV-AQP1: Kadmon Gene Therapy

Product Description

Research and Development

Product Development Activities



Appendix

Drug profiles in the detailed report.....
Inactive Products
Comparative Analysis
Inflammatory Pain Key Companies
Inflammatory Pain Key Products
Inflammatory Pain- Unmet Needs
Inflammatory Pain- Market Drivers and Barriers
Inflammatory Pain- Future Perspectives and Conclusion
Inflammatory Pain Analyst Views
Inflammatory Pain Key Companies



List Of Tables

LIST OF TABLES

Table 1 Total Products for Inflammatory Pain

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products



List Of Figures

LIST OF FIGURES

Figure '	1 Total	Prod	ucts for	· Infl	ammato	ry F	Pain
----------	---------	------	----------	--------	--------	------	------

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products



I would like to order

Product name: Inflammatory Pain - Pipeline Insight, 2021

Product link: https://marketpublishers.com/r/I50B740D2D2FEN.html

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/I50B740D2D2FEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970